Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions
- 1 September 2018
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 30 (5) , 482-489
Abstract
Purpose of review: The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of glucocorticoids and antimalarials in systemic lupus erythematosus (SLE) and provide recommendations on their current use. Recent findings: Glucocorticoid toxicity is well known. Recent data confirm the increased risk of infection and damage accrual. An observational study form Hong Kong has seen increased mortality among users of high-dose prednisone regimes. Several studies support the efficacy of medium-low doses and methyl-prednisolone pulses in lupus patients, both with and without nephritis. New data confirm the effects of antimalarials in preventing SLE activity, damage and infections, and in decreasing mortality. New screening recommendations for hydroxychloroquine maculopathy have been recently published. Combining mepacrine and hydroxychloroquine in patients with refractory cutaneous and/or articular lupus activity has proved highly effective. Summary: Universal therapy with hydroxychloroquine should be aimed to patients with SLE without contraindications. Doses greater than 4 mg/kg/day should be avoided and regular eye screening warranted to minimize the risk of macular toxicity. Every effort should be made to reduce the dose of oral glucocorticoids. In moderate-severe flares, pulse methyl-prednisolone are more effective and much less toxic than increasing the oral doses of prednisone.Keywords
This publication has 53 references indexed in Scilit:
- Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroidsAnnals of the Rheumatic Diseases, 2013
- New insights into mechanisms of therapeutic effects of antimalarial agents in SLENature Reviews Rheumatology, 2012
- Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody–Associated Cardiac Manifestations of Neonatal LupusCirculation, 2012
- Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine RetinopathyOphthalmology, 2011
- Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquineAnnals of the Rheumatic Diseases, 2010
- Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosusArthritis Care & Research, 2010
- Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic reviewAnnals of the Rheumatic Diseases, 2010
- Predictors of major infections in systemic lupus erythematosusArthritis Research & Therapy, 2009
- Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)Annals of the Rheumatic Diseases, 2007
- Antimalarials may influence the risk of malignancy in systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2007